Brussels + 32.2.645.14.47

Katerina Skouteli works on a variety of EU regulatory matters, focusing on the health care and life sciences industry, particularly pharmaceuticals, medical devices, cosmetics, biotechnology, and food.

Katerina advises international clients on life-cycle management from clinical trials and pre-marketing authorization proceedings to post-marketing issues, including product safety, distribution, marketing/advertising, and product liability.

Prior to joining Jones Day, Katerina was a member of the EU regulatory life sciences practice at an international law firm. She also has litigation and dispute resolution experience before the Greek courts.

Katerina has published two legal books on medicinal product liability and clinical trials and is a clinical trials Ph.D. candidate at the University of Athens. She also has lectured on the EU matters of clinical trials at the University of Athens and Aristotle University of Thessaloniki (Greece).


  • Sumitomo Dainippon Pharma acquires late stage biopharma companies and forms alliance with Roivant Sciences Ltd. worth $3 billionJones Day advised Sumitomo Dainippon Pharma Co., Ltd. ("Sumitomo") in an acquisition of late stage biopharma companies and formation of alliance with Roivant Sciences Ltd.
  • Shiseido acquires Drunk Elephant™ for $845 millionJones Day advised Shiseido Americas Corporation in its $845 million acquisition of Drunk Elephant™.
  • ICON acquires Symphony Clinical ResearchJones Day advised ICON plc as health care, clinical trial regulatory, and data privacy diligence counsel in its acquisition of Symphony Clinical Research, a leading provider of at-home patient and site support services.
  • Arsenal Capital Partners acquires HistoGeneX and Caprion BiosciencesJones Day advised Arsenal Capital Partners on major investments in HistoGeneX and Caprion Biosciences and the subsequent combination of the two businesses.
  • Evidera acquires MedimixJones Day advised Evidera, a business unit of Pharmaceutical Product Development, LLC, in its acquisition of Medimix International, a global technology company providing real-world evidence (RWE) insights and information to the pharmaceutical, diagnostic, and medical device industries.
  • We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.